MDSCs in Liver Cancer: A Critical Tumor-promoting Player and a Potential Therapeutic Target

Overview

Journal Cell Immunol

Publisher Elsevier

Specialties Allergy & Immunology
Cell Biology

Date 2021 Jan 28

PMID 33508529

Citations 27

Authors

Chi Ma

Qianfei Zhang

Tim F Greten

Affiliations

Soon will be listed here.

Abstract

Liver cancer is a leading cause of cancer deaths worldwide. Hepatocellular carcinoma (~75-85%) and cholangiocarcinoma (~10-15%) account for the majority of primary liver malignancies. Patients with primary liver cancer are often diagnosed with unresectable diseases and do not respond well to current therapies. The liver is also a common site of metastasis. Liver metastasis is difficult to treat, and the prognosis is poor. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells with immunosuppressive activity. MDSCs are an important component of the tumor microenvironment and promote tumor progression through various mechanisms. MDSCs expand in both liver cancer patients and mouse liver cancer models. Importantly, MDSCs correlate with poor clinical outcomes for liver cancer patients. The tumor-promoting functions of MDSCs have also been shown in mouse liver cancer models. All these studies suggest that targeting MDSCs can potentially benefit liver cancer treatment. This review summarizes the current findings of MDSC regulation in liver cancer and related disease conditions.

Citing Articles

Clinical value of systemic immunoinflammatory index in predicting recurrence and metastasis in patients with primary liver cancer.

Deng Y, Chen Z, He Q, Wu B, Su T, Mao C BMC Gastroenterol. 2025; 25(1):169.

PMID: 40082749 PMC: 11908081. DOI: 10.1186/s12876-025-03749-7.

The Immune-Genomics of Cholangiocarcinoma: A Biological Footprint to Develop Novel Immunotherapies.

Cammarota A, Balsano R, Pressiani T, Bozzarelli S, Rimassa L, Lleo A Cancers (Basel). 2025; 17(2).

PMID: 39858054 PMC: 11763448. DOI: 10.3390/cancers17020272.

Infiltrating T lymphocytes and tumor microenvironment within cholangiocarcinoma: immune heterogeneity, intercellular communication, immune checkpoints.

Dai Y, Dong C, Wang Z, Zhou Y, Wang Y, Hao Y Front Immunol. 2025; 15():1482291.

PMID: 39845973 PMC: 11750830. DOI: 10.3389/fimmu.2024.1482291.

Advancing Cholangiocarcinoma Care: Insights and Innovations in T Cell Therapy.

Dadgar N, Arunachalam A, Hong H, Phoon Y, Arpi-Palacios J, Uysal M Cancers (Basel). 2024; 16(18).

PMID: 39335203 PMC: 11429565. DOI: 10.3390/cancers16183232.

Tumor microenvironment and immunology of cholangiocarcinoma.

Cadamuro M, Fabris L, Zhang X, Strazzabosco M Hepatoma Res. 2024; 8.

PMID: 39301518 PMC: 11412615. DOI: 10.20517/2394-5079.2021.140.

References

Anstee Q, Reeves H, Kotsiliti E, Govaere O, Heikenwalder M . From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019; 16(7):411-428. DOI: 10.1038/s41575-019-0145-7. View

Shen P, Wang A, He M, Wang Q, Zheng S . Increased circulating Lin(-/low) CD33(+) HLA-DR(-) myeloid-derived suppressor cells in hepatocellular carcinoma patients. Hepatol Res. 2013; 44(6):639-50. DOI: 10.1111/hepr.12167. View

Noman M, Desantis G, Janji B, Hasmim M, Karray S, Dessen P . PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014; 211(5):781-90. PMC: 4010891. DOI: 10.1084/jem.20131916. View

Morse M, Sun W, Kim R, He A, Abada P, Mynderse M . The Role of Angiogenesis in Hepatocellular Carcinoma. Clin Cancer Res. 2018; 25(3):912-920. DOI: 10.1158/1078-0432.CCR-18-1254. View

Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20):1894-1905. DOI: 10.1056/NEJMoa1915745. View

Kumar V, Patel S, Tcyganov E, Gabrilovich D . The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends Immunol. 2016; 37(3):208-220. PMC: 4775398. DOI: 10.1016/j.it.2016.01.004. View

Xu Y, Fang F, Jiao H, Zheng X, Huang L, Yi X . Activated hepatic stellate cells regulate MDSC migration through the SDF-1/CXCR4 axis in an orthotopic mouse model of hepatocellular carcinoma. Cancer Immunol Immunother. 2019; 68(12):1959-1969. PMC: 11028284. DOI: 10.1007/s00262-019-02414-9. View

Tyson G, El-Serag H . Risk factors for cholangiocarcinoma. Hepatology. 2011; 54(1):173-84. PMC: 3125451. DOI: 10.1002/hep.24351. View

Monu N, Frey A . Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship. Immunol Invest. 2012; 41(6-7):595-613. PMC: 3701882. DOI: 10.3109/08820139.2012.673191. View

10.

Lin Y, Li B, Yang X, Cai Q, Liu W, Tian M . Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment. Neoplasia. 2019; 21(12):1133-1142. PMC: 6880109. DOI: 10.1016/j.neo.2019.10.005. View

11.

Razumilava N, Gores G . Cholangiocarcinoma. Lancet. 2014; 383(9935):2168-79. PMC: 4069226. DOI: 10.1016/S0140-6736(13)61903-0. View

12.

Obstfeld A, Sugaru E, Thearle M, Francisco A, Gayet C, Ginsberg H . C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes. 2010; 59(4):916-25. PMC: 2844839. DOI: 10.2337/db09-1403. View

13.

Bonnardel J, TJonck W, Gaublomme D, Browaeys R, Scott C, Martens L . Stellate Cells, Hepatocytes, and Endothelial Cells Imprint the Kupffer Cell Identity on Monocytes Colonizing the Liver Macrophage Niche. Immunity. 2019; 51(4):638-654.e9. PMC: 6876284. DOI: 10.1016/j.immuni.2019.08.017. View

14.

Banales J, Cardinale V, Carpino G, Marzioni M, Andersen J, Invernizzi P . Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016; 13(5):261-80. DOI: 10.1038/nrgastro.2016.51. View

15.

Liu M, Zhou J, Liu X, Feng Y, Yang W, Wu F . Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Gut. 2019; 69(2):365-379. DOI: 10.1136/gutjnl-2018-317257. View

16.

Welzel T, Graubard B, El-Serag H, Shaib Y, Hsing A, Davila J . Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007; 5(10):1221-8. PMC: 2083573. DOI: 10.1016/j.cgh.2007.05.020. View

17.

Lee J, Stone M, Porrett P, Thomas S, Komar C, Li J . Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature. 2019; 567(7747):249-252. PMC: 6430113. DOI: 10.1038/s41586-019-1004-y. View

18.

Lee C, Kwak Y, Yang T, Han J, Park S, Ye M . Myeloid-Derived Suppressor Cells Are Controlled by Regulatory T Cells via TGF-β during Murine Colitis. Cell Rep. 2016; 17(12):3219-3232. DOI: 10.1016/j.celrep.2016.11.062. View

19.

Alshetaiwi H, Pervolarakis N, McIntyre L, Ma D, Nguyen Q, Rath J . Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci Immunol. 2020; 5(44). PMC: 7219211. DOI: 10.1126/sciimmunol.aay6017. View

20.

Vetsika E, Koukos A, Kotsakis A . Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer. Cells. 2019; 8(12). PMC: 6953061. DOI: 10.3390/cells8121647. View